Granulocyte colony-stimulating factor in bronchoalveolar lavage fluid is a potential biomarker for prognostic prediction of idiopathic pulmonary fibrosis
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Neutrophilia is frequently observed in bronchoalveolar lavage fluid (BALF) of idiopathic pulmonary fibrosis (IPF) patients. Granulocyte colony-stimulating factor (G-CSF) is a potent neutrophil-activating glycoprotein. However, the clinical implications of G-CSF remain poorly understood.in patients with IPF. Therefore, we evaluated the relationship between the G-CSF concentration in BALF and the progression of fibrosis, including in terms of the decline in lung function and long-term survival rate. Methods: G-CSF concentrations were measured in BALF using enzyme-linked immunosorbent assay (ELISA). The survival rate was estimated using Kaplan-Meier survival analyses. Results: G-CSF protein levels were significantly higher in IPF (n = 87; 1.88 [0 to 5.68 pg/mL]), nonspecific interstitial pneumonia (n = 22; 0.58 [0 to 11.64 pg/mL]), and hypersensitivity pneumonitis (n = 19; 2.48 [0.46 to 5.71 pg/mL]) patients than in normal controls (n = 33; 0 [0 to 0.68 pg/mL]) (all p < 0.01). A receiver operating characteristic curve showed a difference in G-CSF levels between IPF and NC (area under the curve, 0.769): The G-CSF cut-off of 0.96 pg/mL indicated 84.9% specificity and 63.2% sensitivity for IPF. The survival rate was significantly lower in the group with G-CSF > 2.872 pg/mL than in the group with ≤ 2.872 pg/mL (hazard ratio, 2.69; p = 0.041). The annual decline in diffusing capacity of the lung for carbon monoxide was positively correlated with the G-CSF level (p = 0.018). Conclusions: G-CSF may participate in the development of IPF and be useful for predicting the prognosis of IPF. Therefore, G-CSF should be analyzed in BALF, in addition to differential cell counts.
Abstract
Background/Aims: Neutrophilia is frequently observed in bronchoalveolar lavage fluid (BALF) of idiopathic pulmonary fibrosis (IPF) patients. Granulocyte colony-stimulating factor (G-CSF) is a potent neutrophil-activating glycoprotein. However, the clinical implications of G-CSF remain poorly understood.in patients with IPF. Therefore, we evaluated the relationship between the G-CSF concentration in BALF and the progression of fibrosis, including in terms of the decline in lung function and long-term survival rate. Methods: G-CSF concentrations were measured in BALF using enzyme-linked immunosorbent assay (ELISA). The survival rate was estimated using Kaplan-Meier survival analyses. Results: G-CSF protein levels were significantly higher in IPF (n = 87; 1.88 [0 to 5.68 pg/mL]), nonspecific interstitial pneumonia (n = 22; 0.58 [0 to 11.64 pg/mL]), and hypersensitivity pneumonitis (n = 19; 2.48 [0.46 to 5.71 pg/mL]) patients than in normal controls (n = 33; 0 [0 to 0.68 pg/mL]) (all p < 0.01). A receiver operating characteristic curve showed a difference in G-CSF levels between IPF and NC (area under the curve, 0.769): The G-CSF cut-off of 0.96 pg/mL indicated 84.9% specificity and 63.2% sensitivity for IPF. The survival rate was significantly lower in the group with G-CSF > 2.872 pg/mL than in the group with ≤ 2.872 pg/mL (hazard ratio, 2.69; p = 0.041). The annual decline in diffusing capacity of the lung for carbon monoxide was positively correlated with the G-CSF level (p = 0.018). Conclusions: G-CSF may participate in the development of IPF and be useful for predicting the prognosis of IPF. Therefore, G-CSF should be analyzed in BALF, in addition to differential cell counts.
참고문헌 (40)
- Ley B, "Clinical course and prediction of survival in idiopathic pulmonary fibrosis", Am J Respir Crit Care Med, 183, pp.431~440 (2011)
- Liu YM, "Idiopathic pulmonary fibrosis : current status, recent progress, and emerging targets", J Med Chem, 60, pp.527~553 (2017)
- Desai O, "The role of immune and inflammatory cells in idiopathic pulmonary fibrosis", Front Med(Lausanne), 5, pp.43~ (2018)
- Coward WR, "The pathogenesis of idiopathic pulmonary fibrosis", Ther Adv Respir Dis, 4, pp.367~388 (2010)
- Zolak JS, "Idiopathic pulmonary fibrosis", Immunol Allergy Clin North Am, 32, pp.473~485 (2012)
- Giannandrea M, "Diverse functions of matrix metalloproteinases during fibrosis", Dis Model Mech, 7, pp.193~203 (2014)
- Kruger P, "Neutrophils : Between host defence, immune modulation, and tissue injury", PLoS Pathog, 11, pp.e1004651~ (2015)
- Kaplan MJ, "Neutrophil extracellular traps : double-edged swords of innate immunity", J Immunol, 189, pp.2689~2695 (2012)
- Chrysanthopoulou A, "Neutrophil extracellular traps promote differentiation and function of fibroblasts", J Pathol, 233, pp.294~307 (2014)
- Kinder BW, "Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis", Chest, 133, pp.226~232 (2008)
- Watters LC, "Idiopathic pulmonary fibrosis : pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy", Am Rev Respir Dis, 135, pp.696~704 (1987)
- Tabuena RP, "Cell profiles of bronchoalveolar lavage fluid as prognosticators of idiopathic pulmonary fibrosis", usual interstitial pneumonia among Japanese patients, 2005, pp.72, 490~498
- Obayashi Y, "The role of neutrophils in the pathogenesis of idiopathic pulmonary fibrosis", Chest, 112, pp.1338~1343 (1997)
- Pardo A, "Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis", Respir Res, 17, pp.23~ (2016)
- Inage M, "Levels of cytokeratin 19fragments in bronchoalveolar lavage fluid correlate to the intensity of neutrophil and eosinophil-alveolitis in patients with idiopathic pulmonary fibrosis", Respir Med, 94, pp.155~160 (2000)
- Rajarathnam K, "How do chemokines navigate neutrophils to the target site : dissecting the structural mechanisms and signaling pathways", Cell Signal, 54, pp.69~80 (2019)
- Roberts AW, "G-CSF: a key regulator of neutrophil production, but that’s not all!", Growth Factors, 23, pp.33~41 (2005)
- Boneberg EM, "Human monocytes express functional receptors for granulocyte colony-stimulating factor that mediate suppression of monokines and interferon-gamma", Blood, 95, pp.270~276 (2000)
- Kisseleva T, "Fibrocyte-like cells recruited to the spleen support innate and adaptive immune responses to acute injury or infection", J Mol Med(Berl), 89, pp.997~1013 (2011)
- Ashitani J, "Granulocyte-colony stimulating factor levels in bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis", Thorax, 54, pp.1015~1020 (1999)
- Hamilton JA, "Colony-stimulating factors in inflammation and autoimmunity", Nat Rev Immunol, 8, pp.533~544 (2008)
- Hamilton JA, "Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases", Nat Rev Drug Discov, 16, pp.53~70 (2016)
- Cetean S, "The importance of the granulocyte-colony stimulating factor in oncology", Clujul Med, 88, pp.468~472 (2015)
- Sano E, "A possible role of autogenous IFN-beta for cytokine productions in human fibroblasts", J Cell Biochem, 100, pp.1459~1476 (2007)
- Jones CE, "Interleukin-17 stimulates the expression of interleukin-8, growth-related oncogene-alpha, and granulocyte-colony-stimulating factor by human airway epithelial cells", Am J Respir Cell Mol Biol, 26, pp.748~753 (2002)
- Azoulay E, "Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity : myth or reality? : systematic review of clinical case reports and experimental data", Chest, 120, pp.1695~1701 (2001)
- Zhao FY, "G-CSF inhibits pulmonary fibrosis by promoting BMSC homing to the lungs via SDF-1", CXCR4 chemotaxis, 2020, pp.10, 10515~
- Zhang F, "Mobilization of bone marrow cells by CSF3 protects mice from bleomycin-induced lung injury", Respiration, 82, pp.358~368 (2011)
- Raghu G, "An official ATS", ERS, ALAT statement : idiopathic pulmonary fibrosis : evidence-based guidelines for diagnosis and management, pp.Am J Respir Crit Care Med, 2011[DOI]
- Raghu G, "Diagnosis of idiopathic pulmonary fibrosis : an official ATS", ERS, ALAT Clinical Practice Guideline, pp.Am J Respir Crit Care Med, 2018[DOI]
- Travis WD, "An official American Thoracic Society", European Respiratory Society statement : update of the international multidisciplinary classification of the idiopathic interstitial pneumonias, 2013, pp.188, 733~748
- Erratum, "diagnosis of hypersensitivity pneumonitis in adults : an official ATS", JRS, Am J Respir Crit Care Med, pp.2021, 203[DOI]
- Crouser ED, "Diagnosis and detection of sarcoidosis : an official American Thoracic Society Clinical Practice Guideline", Am J Respir Crit Care Med, 201, pp.e26~e51 (2020)
- Venables KM, "Respiratory symptoms questionnaire for asthma epidemiology : validity and reproducibility", Thorax, 48, pp.214~219 (1993)
- 박성우, "Interleukin-13 and Its Receptors in Idiopathic Interstitial Pneumonia: Clinical Implications for Lung Function", Journal of Korean Medical Science, 24(4), pp.614~620 (2009), 대한의학회
- DeLong ER, "Comparing the areas under two or more correlated receiver operating characteristic curves : a nonparametric approach", Biometrics, 44, pp.837~845 (1988)
- D’Souza A, "Granulocyte colony-stimulating factor administration : adverse events", Transfus Med Rev, 22, pp.280~290 (2008)
- Ley B, "A multidimensional index and staging system for idiopathic pulmonary fibrosis", Ann Intern Med, 156, pp.684~691 (2012)
- King TE Jr, "A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis", N Engl J Med, 370, pp.2083~2092 (2014)
- Richeldi L, "Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis", N Engl J Med, 370, pp.2071~2082 (2014)